Precision Neuroscience announces $250 million Series D
Source publication date
Summary
Precision Neuroscience announced the closing of a $250 million Series D. It plans to expand clinical work, advance Layer 7 through further FDA review, and build commercialization infrastructure.
Editorial view
Editorial view: Clinical execution and commercialization capacity are important comparison points alongside electrode technology.
Evidence and limitations
Company financing announcement and planned use of proceeds. Funding does not establish permanent-implant authorization or clinical efficacy.